Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001071
UniProt IDP14324
Primary gene name(s)FDPS
Synonym gene name(s)FPS, KIAA1293
Protein nameFarnesyl pyrophosphate synthase
Protein functionKey enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate, FPP, a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
Subcellular locationCytoplasm.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P14324
Gene Ontology
(Biological Process)
Complete annatation
cholesterol biosynthetic process [GO:0006695];
farnesyl diphosphate biosynthetic process [GO:0045337];
geranyl diphosphate biosynthetic process [GO:0033384];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
dimethylallyltranstransferase activity [GO:0004161];
geranyltranstransferase activity [GO:0004337];
metal ion binding [GO:0046872];
poly(A RNA binding [GO:0044822]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
nucleoplasm [GO:0005654]
Protein-protein interaction108517
Phylogenetic treeP14324
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.5434908341187410.09873132754229130.17418688618956
AZA vs. DISU-0.2146668419807270.39647540566690.902957406378847
AZA vs. IL70.1955076204174210.3098424262323510.999311006273513
AZA vs. SAHA-0.1754150460084010.4727016788359810.805931508933019
DISU vs. CD3-0.7696055902672520.03493048723776190.0810189513189757
DISU vs. IL70.4004245665314140.1124812554456670.439516569684662
DISU vs. SAHA0.04110722412467820.8878220427685190.971874193603508
DMSO vs. AZA0.01576451516431260.9251876889011211
DMSO vs. CD3-0.5384338305277860.09378094753269160.162241124369074
DMSO vs. DISU0.2286257137962990.3491161744121840.842312150921815
DMSO vs. IL70.1870196175125640.2988947533778060.784531259250773
DMSO vs. SAHA-0.1970591221018560.4037595245754760.746770759645673
HIV vs. Mock in Activation-0.06325687085951880.9189535559706430.999983755607037
HIV vs. Mock in Latency0.077724260068330.6392511991237780.999834320637052
IL7 vs. CD3-0.3416965055004510.2885377507183060.425717454637532
SAHA vs. CD3-0.7422540385654470.03670483015976430.0768786366237177
SAHA vs. IL7-0.3730359331742310.126175506055970.330031160556602
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.668374 0.361212
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.082 0.955 1.468 1.665 0.849
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00282 Pamidronate approved yes inhibitor
DB00399 Zoledronic acid approved yes inhibitor
DB00630 Alendronic acid approved yes inhibitor
DB00710 Ibandronate approved, investigational yes inhibitor
DB00884 Risedronate approved, investigational yes inhibitor
DB04714 ISOPENTENYL PYROPHOSPHATE experimental unknown unknown
DB01785 Dimethylallyl Diphosphate experimental unknown unknown
DB07780 FARNESYL DIPHOSPHATE experimental unknown unknown
DB02552 Geranyl Diphosphate experimental unknown unknown
DB07841 GERANYLGERANYL DIPHOSPHATE experimental unknown unknown
DB02508 Isopentyl Pyrophosphate experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1YQ7 X-ray 2.2Å A=67-419.
1YV5 X-ray 2.0Å A=67-419.
1ZW5 X-ray 2.3Å A=67-419.
2F7M X-ray 2.3Å F=72-419.
2F89 X-ray 2.6Å F=72-419.
2F8C X-ray 2.2Å F=72-419.
2F8Z X-ray 2.6Å F=72-419.
2F92 X-ray 2.1Å F=72-419.
2F94 X-ray 1.9Å F=72-419.
2F9K X-ray 2.0Å F=72-419.
2OPM X-ray 2.4Å A=67-419.
2OPN X-ray 2.7Å A=67-419.
2QIS X-ray 1.8Å A=67-419.
2RAH X-ray 2.0Å A=67-419.
2VF6 X-ray 2.1Å A=67-419.
3B7L X-ray 1.9Å A=67-419.
3CP6 X-ray 1.9Å A=67-419.
3N1V X-ray 2.1Å F=72-419.
3N1W X-ray 2.5Å F=72-419.
3N3L X-ray 2.7Å F=72-419.
3N45 X-ray 1.8Å F=72-419.
3N46 X-ray 2.3Å F=72-419.
3N49 X-ray 2.5Å F=72-419.
3N5H X-ray 2.2Å F=72-419.
3N5J X-ray 2.3Å F=72-419.
3N6K X-ray 2.2Å F=72-419.
3RYE X-ray 2.1Å A=71-419.
3S4J X-ray 1.9Å A=71-419.
4DEM X-ray 1.8Å F=67-419.
4GA3 X-ray 2.3Å A=72-419.
4H5C X-ray 2.0Å F=67-419.
4H5D X-ray 2.0Å F=67-419.
4H5E X-ray 2.0Å F=67-419.
4JVJ X-ray 2.8Å F=67-419.
4KFA X-ray 1.9Å A=67-419.
4KPD X-ray 1.9Å A=67-419.
4KPJ X-ray 1.9Å A=67-419.
4KQ5 X-ray 2.4Å A=67-419.
4KQS X-ray 1.9Å A=67-419.
4KQU X-ray 2.0Å A=67-419.
4L2X X-ray 2.5Å F=67-419.
4LFV X-ray 2.0Å F=67-419.
4LPG X-ray 2.3Å F=67-419.
4LPH X-ray 2.3Å F=67-419.
4N1Z X-ray 2.3Å F=72-419.
4N9U X-ray 2.1Å A=67-419.
4NFI X-ray 1.8Å F=67-419.
4NFJ X-ray 2.0Å F=67-419.
4NFK X-ray 1.8Å F=67-419.
4NG6 X-ray 2.3Å A=67-419.
4NKE X-ray 1.4Å A=67-419.
4NKF X-ray 2.0Å A=67-419.
4NUA X-ray 1.4Å A=67-419.
4OGU X-ray 2.1Å A=67-419.
4P0V X-ray 2.4Å A=73-419.
4P0W X-ray 2.4Å A=72-419.
4P0X X-ray 2.5Å A=72-419.
4PVX X-ray 2.1Å F=67-419.
4PVY X-ray 2.0Å F=67-419.
4Q23 X-ray 1.9Å A=67-419.
4QPF X-ray 1.5Å A=67-419.
4QXS X-ray 1.9Å F=67-419.
4RXA X-ray 2.2Å A=72-419.
4XQR X-ray 2.1Å F=67-419.
4XQS X-ray 2.3Å F=67-419.
4XQT X-ray 2.1Å F=67-419.
5CG5 Other 1.4Å A=74-419.
5CG6 Other 1.7Å A=74-419.
5DGM X-ray 2.8Å F=72-419.
5DGN X-ray 2.0Å F=72-419.
5DGS X-ray 2.6Å F=72-419.
5DIQ X-ray 2.1Å F=72-419.
5DJP X-ray 2.4Å F=72-419.
5DJR X-ray 2.4Å F=72-419.
5DJV X-ray 2.3Å F=72-419.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00900 Terpenoid backbone biosynthesis - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)